TECVAYLI® Plus DARZALEX FASPRO® Wins FDA Approval for Relapsed/Refractory Multiple Myeloma
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed or Refractory Multiple Myeloma Halozyme Therapeutics has announced that Johnson & Johnson has received approval from the U.S. Food…
Celltrion Plans to Cancel 9.11 Million Treasury Shares to Boost Shareholder Value Amid Market Uncertainty
Celltrion Plans Cancellation of 9.11 Million Treasury Shares to Strengthen Shareholder Value Amid Market Volatility Celltrion has announced a significant corporate governance and capital management initiative aimed at strengthening shareholder…
European Commission Approves Zynyz for First-Line Treatment of Advanced Anal Cancer, Says Incyte
European Commission Approves Zynyz® (retifanlimab) as a First-Line Treatment for Patients with Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Incyte has announced that the European Commission has granted…
NEJM Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Reduces Lupus Disease Activity
NEJM Publishes Phase III ALLEGORY Results Showing Gazyva Reduces Disease Activity in Common Lupus Genentech, a member of the Roche Group, has announced that detailed results from the Phase III…
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 for Long-Term Post-GLP-1 Weight Management
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for…
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus Mirum Pharmaceuticals, Inc. a leading rare disease company, today announced completion of enrollment in the Phase…
DiaMedica Therapeutics Receives Health Canada Clearance to Launch Phase 2 Study of DM199 for Preeclampsia
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal…
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full-Year 2025 Financial Results
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results Silence Therapeutics plc, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies,…
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells,…
Parabilis Medicines Reports Early Clinical Evidence Showing Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for…
Verastem Oncology Reports 2025 Financial Results and Updates
Verastem Oncology Reports Strong Progress in 2025 with Drug Launch, Pipeline Advances, and Financial Updates Verastem Oncology reported its financial results for the fourth quarter and full year ending December 31, 2025,…
Xencor Updates Forecast for Ultomiris® Royalty Revenue
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals,…